Michael D. Lockshin

Michael D. Lockshin
Michael D. Lockshin
Born 1937
Columbus, Ohio
Education Harvard University
Relatives Richard A. Lockshin (twin brother)
Specialism Rheumatology
Notable prizes New York Arthritis Foundation Lifetime Achievement Award

Michael D. Lockshin, M.D., is an American professor and medical researcher. He is a researcher of autoimmune diseases, with focus on antiphospholipid syndrome and lupus. He is currently Professor of Medicine and Obstetrics-Gynecology at the Weill-Cornell University Medical College in New York City.

Locksin's twin brother, Richard A. Lockshin, is an American cellular biologist known for his work on apoptosis.

Contents

Education and training

Lockshin graduated cum laude from Harvard College with an BA in history and literature. He received his MD from Harvard Medical School. Lockshin interned and did his residency at Bellevue Hospital and Memorial Hospital for Cancer and Allied Diseases and his fellowship in Rheumatic Diseases at Columbia Presbyterian Medical Center in New York City.

Work

His long-term research interest is in the clinical aspects of systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), pregnancy in rheumatic disease patients, gender and rheumatic disease, and neurological SLE. His research has been supported by grants from NIAMS, the Arthritis Foundation, the SLE Foundation, and private donors throughout his academic career.

He is director of the Barbara Volcker Center for Women and Rheumatic Disease and co-director of the Mary Kirkland Center for Lupus Research at the Hospital for Special Surgery.

Locksin served as editor-in-chief of Arthritis & Rheumatism for five years.[1] He has also served on the editorial board of the Journal of Rheumatology, and as a reviewer for the New England Journal of Medicine, the Journal of Clinical Investigation, and the Journal of Immunology.

Lockshin has held senior management positions at the National Institutes of Health in Bethesda, Maryland. He served first as director of the Extramural Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and then as acting director of the Institute. This Institute is responsible for U.S. government research funding in the fields of rheumatology and dermatology. He also served as Senior Advisor to the Director at the NIH's Warren G. Magnuson Clinical Center.

Honors

Lockshin received a Lifetime Achievement Award from the New York Arthritis Foundation in 2008. He was named a master of the American College of Rheumatology in 2003 and a Research Hero of the Arthritis Foundation in 2001. He is an honorary faculty member of Alpha Omega Alpha.

Committee membership

He has served on numerous study sections and ad-hoc committees for the National Institutes of Health, the Veterans' Administration, the Canadian Arthritis and Rheumatism Society, the Canadian Medical Research Council, the SLE Foundation, among others.

  • Institute of Medicine Health Science Policy Committee, 2002-5
  • National Academy of Sciences, Institute of Medicine, AXXS Workshop, 2002
  • Institute of Medicine Committee on CDC’s Safety and Efficacy Research on Anthrax Vaccine, 2001-2
  • Advisory Committee on Research on Women’s Health, National Institutes of Health, 2001-5
  • Autoimmunity Centers of Excellence, Data and Safety Monitoring Committee, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 2000-4
  • Institute of Medicine Committee on Understanding the Biology of Sex and Gender Differences, 1999–2001
  • Alliance for Lupus Research, Scientific Executive Board, 2000-
  • American Rheumatism Association: many committees and offices, including Education Committee (Chairman), Committee on Rheumatologic Practice (Chairman), Second Vice President, and Abstract Review Committees (Chairman)
  • Arthritis Foundation: many committees and offices, including Board of Governors, Professional Education Committee (Chairman), Unproven Remedies Committee (Chairman)
  • American Board of Internal Medicine: Sub Specialty Committee on Rheumatology (Chairman )
  • American College of Physicians: Medical Knowledge Self-Assessment Program IX (Chairman)
  • American Board of Medical Examiners: Member for Rheumatology
  • SLE Foundation of America, Inc.: Medical Advisory Committee (Chairman)

Scientific publications

RELEVANT PEER-REVIEWED PUBLICATIONS (selected 2005–present, of 200+ total, includes reviews)

  • Buyon JP, Petri MA; Kim MY, Kalunian K, Grossman J, Hahn BH, Merrill JT, Sammaritano L, Lockshin M, Alarcon G, Manzi S, Belmont HM, Askanase AD, Sigler L, Dooley MA, Von Feldt J, McCune WJ, Alan Friedman F, Wachs J, Cronin M, Hearth-Holmes M, Tan M, MD Licciardi F, for the SELENA Investigators. Estrogen/cyclic progesterone replacement is associated with an increased rate of mild/moderate but not severe flares in SLE. Ann Intern Med 2005; 142:953-962.
  • Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Elfi Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005;46:1-6.
  • Tenedios F, Erkan D, Lockshin MD. Cardiac involvement in the antiphospholipid syndrome. Lupus 2005; 14: 691-6.
  • Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP; OC- SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.
  • Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2006 Jul 25;54(8):2515-2522 [Epub ahead of print]
  • Ostensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, Doria A, Rai R, Meroni P, Cetin I, Derksen R, Branch W, Motta M, Gordon C, Ruiz-Irastorza G, Spinillo A, Friedman D, Cimaz R, Czeizel A, Piette JC, Cervera R, Levy RA, Clementi M, De Carolis S, Petri M, Shoenfeld Y, Faden D, Valesini G, Tincani A. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209. Epub 2006 May 11.
  • Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, Sammaritano L, Devereux RB, Schwartz JE, Levine DM, Salmon JE. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med. 2006 Feb 21;144(4):249-56. Summary for patients in: Ann Intern Med. 2006 Feb 21;144(4):I38.
  • Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306.
  • Lockshin MD. Sex differences in autoimmune disease. Lupus 2006;15:1-4.
  • Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006 Dec;54(12):3918-25
  • Lockshin MD; Mary Kirkland Center for Lupus Research Consortium. Biology of the sex and age distribution of systemic lupus erythematosus. Arthritis Rheum. 2007 May 15;57(4):608-11.
  • Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007 Jul;56(7):2382-91.
  • Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, Schwartz JE, Sammaritano L, Levine DM, Salmon JE. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation. 2007 Jul 24;116(4):419-26.
  • Kaul MS, Erkan D, Sammaritano L, Lockshin MD, Assessment of the 2006 revised antiphospholipid syndrome classification criteria, Ann Rheum Dis 2007;66:927–930
  • Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007 Oct;56(10):3412-9.
  • Salmon JE, Girardi G, Lockshin MD. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol. 2007 Mar;3(3):140-7
  • Doria A, Tincani A, Lockshin M. Challenges of lupus pregnancies. Rheumatology (Oxford). 2008 Jun;47 Suppl 3:iii9-12. PMID: 18504287 [PubMed - in process]
  • Østensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C, Brucato A, Tincani A. Update in safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford). 2008 Jun;47 Suppl 3:iii28-31. PMID: 18504282 [PubMed - in process]
  • Cutolo M, Matucci-Cerinic M, Lockshin M, Ostensen M. Introduction: new trends in pregnancy and rheumatic diseases. Rheumatology (Oxford). 2008 Jun;47 Suppl 3:iii1.

Books

  • Dancing at the River's Edge: A Patient and Her Doctor Negotiate Life with Chronic Illness by Alida Brill and Michael D. Lockshin, M.D. (Hardcover, Schaffner Press, January 2009)
  • The Hospital for Special Surgery Rheumatoid Arthritis Handbook by Stephen A. Paget, M.D., Michael D. Lockshin M.D., and Suzanne Loeb (Paperback, Wiley October 2001)
  • Guarded Prognosis: A Doctor and His Patients Talk About Chronic Disease and How to Cope With It by Michael D. Lockshin, M.D. (Hardcover, Farrar Straus & Giroux, June 1998)

References

  1. ^ Wiley online library, "Introducing the new editor of Arthritis & Rheumatism, Michael D. Lockshin, MD", June 28, 2005, retrieved May 5, 2011.

External links


Wikimedia Foundation. 2010.

Игры ⚽ Поможем написать курсовую

Look at other dictionaries:

  • Systemic lupus erythematosus — For other uses, see lupus (disambiguation). Systemic lupus erythematosus Classification and external resources The typical butterfly rash found in lupus ICD 10 L …   Wikipedia

  • Lupus érythémateux disséminé — Pour les articles homonymes, voir Lupus et LED. Lupus érythémateux disséminé Classification et ressources externes …   Wikipédia en Français

  • Lupus erythemateux dissemine — Lupus érythémateux disséminé Pour les articles homonymes, voir Lupus et LED. Lupus érythémateux disséminé Classification et ressources externes …   Wikipédia en Français

  • Lupus erythematosus — Lupus érythémateux disséminé Pour les articles homonymes, voir Lupus et LED. Lupus érythémateux disséminé Classification et ressources externes …   Wikipédia en Français

  • Lupus Érythémateux Disséminé — Pour les articles homonymes, voir Lupus et LED. Lupus érythémateux disséminé Classification et ressources externes …   Wikipédia en Français

  • Lupus eritematoso sistémico — Saltar a navegación, búsqueda Lupus eritematoso sistémico Clasificación y recursos externos Aviso médico …   Wikipedia Español

  • Lupus — Para otros términos denominados lupus, véase Lupus (desambiguación). Lupus Eritematoso Sistémico Ilustración del eritema malar clásico del LES. Clasificaci …   Wikipedia Español

  • Системная красная волчанка — У этого термина существуют и другие значения, см. Волчанка. Системная красная волчанка …   Википедия

  • History and highlights in apoptosis research — A timeline of apoptosis research can be found in [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve db=pubmed dopt=Abstract list uids=11965486 query hl=2 Cell Death and Differentiation (2002) 9:349 54] Apoptosis is the process of… …   Wikipedia

  • Peshat — (also P shat, פשט) is one of four classical methods of Jewish biblical exegesis used by Rabbis and Jewish bible scholars in reading the Hebrew Bible, also known as the Tanakh. Peshat is part of a group of exegetical methods known together as… …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”